{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T20:03:06Z","timestamp":1763755386122,"version":"3.45.0"},"reference-count":40,"publisher":"Oncology Nursing Society (ONS)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncology Nursing Forum"],"published-print":{"date-parts":[[2004,5,1]]},"DOI":"10.1188\/04.onf.569-576","type":"journal-article","created":{"date-parts":[[2007,8,23]],"date-time":"2007-08-23T10:47:07Z","timestamp":1187866027000},"page":"569-576","source":"Crossref","is-referenced-by-count":8,"title":["Optimal Use of Granulocyte-Colony-Stimulating Factor in Patients With Cancer Who Are at Risk for Chemotherapy-Induced Neutropenia"],"prefix":"10.1188","volume":"31","author":[{"given":"Carrie","family":"Cappozzo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1302","published-online":{"date-parts":[[2007,2,8]]},"reference":[{"key":"E00001","unstructured":"Balducci, L., & Yates, J. (2000). General guidelines for the management of older patients with cancer. <i>Oncology (Huntington), 14<\/i>, 221-227."},{"key":"E00002","doi-asserted-by":"crossref","unstructured":"Feld, R. (2000). Multinational cooperation in trials and guidelines dealing with febrile neutropenia. <i>International Journal of Antimicrobial Agents, 16<\/i>, 185-187.","DOI":"10.1016\/S0924-8579(00)00240-5"},{"key":"E00003","doi-asserted-by":"crossref","unstructured":"Frampton, J.E., Lee, C.R., & Faulds, D. (1994). Filgrastim: A review of its pharmacological properties and therapeutic efficacy in neutropenia. <i>Drugs, 48<\/i>, 731-760.","DOI":"10.2165\/00003495-199448050-00007"},{"key":"E00004","unstructured":"Fujisawa, M., Kobayashi, Y., Okabe, T., Takaku, F., Komatsu, Y., & Itoh, S. (1986). Recombinant human granulocyte colony-stimulating factor induces granulocytosis in vivo. <i>Japanese Journal of Cancer Research, 77<\/i>, 866-869."},{"key":"E00005","unstructured":"George, S., Yunus, F., Yang, B.B., Hackett, J., Neumann, T., & Liang, B. (2001). Pharmacokinetic profiles of fixed dose single pegfilgrastim administration in patients with non-Hodgkin's lymphoma [Abstract]. <i>Blood, 98<\/i>(Suppl. 2), 27b."},{"key":"E00006","doi-asserted-by":"crossref","unstructured":"G\u00f3mez, H., Hidalgo, M., Casanova, L., Colomer, R., Pen, D.L., Otero, J., et al. (1998). Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: Results of a multivariate analysis. <i>Journal of Clinical Oncology, 16<\/i>, 2065-2069.","DOI":"10.1200\/JCO.1998.16.6.2065"},{"key":"E00007","doi-asserted-by":"crossref","unstructured":"Green, M.D., Koelbl, H., Baselga, J., Galid, A., Guillem, V., Gascon, P., et al. (2003). A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. <i>Annals of Oncology, 14<\/i>, 29-35.","DOI":"10.1093\/annonc\/mdg019"},{"key":"E00008","doi-asserted-by":"crossref","unstructured":"Hartmann, L.C., Tschetter, L.K., Habermann, T.M., Ebbert, L.P., Johnson, P.S., Mailliard, J.A., et al. (1997). Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. <i>New England Journal of Medicine, 336<\/i>, 1776-1780.","DOI":"10.1056\/NEJM199706193362502"},{"key":"E00009","doi-asserted-by":"crossref","unstructured":"Holmes, F.A., Jones, S.E., O'Shaughnessy, J., Vukelja, S., George, T., Savin, M., et al. (2002). Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: A multicenter dose-finding study in women with breast cancer. <i>Annals of Oncology, 13<\/i>, 903-909.","DOI":"10.1093\/annonc\/mdf130"},{"key":"E00010","doi-asserted-by":"crossref","unstructured":"Holmes, F.A., O'Shaughnessy, J.A., Vukelja, S., Jones, S.E., Shogan, J., Savin, M., et al. (2002). Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III\/IV breast cancer. <i>Journal of Clinical Oncology, 20<\/i>, 727-731.","DOI":"10.1200\/JCO.2002.20.3.727"},{"key":"E00011","doi-asserted-by":"crossref","unstructured":"Intragumtornchai, T., Sutheesophon, J., Sutcharitchan, P., & Swasdikul, D. (2000). A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma, 37<\/i>, 351-360.","DOI":"10.3109\/10428190009089435"},{"key":"E00012","doi-asserted-by":"crossref","unstructured":"Johnston, E., Crawford, J., Blackwell, S., Bjurstrom, T., Lockbaum, P., Roskos, L., et al. (2000). Randomized, dose-escalation study of SD\/01 compared with daily filgrastim in patients receiving chemotherapy. <i>Journal of Clinical Oncology, 18<\/i>, 2522-2528.","DOI":"10.1200\/JCO.2000.18.13.2522"},{"key":"E00013","doi-asserted-by":"crossref","unstructured":"Kwak, L.W., Halpern, J., Olshen, R.A., & Horning, S.J. (1990). Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: Results of a tree-structured survival analysis. <i>Journal of Clinical Oncology, 8<\/i>, 963-977.","DOI":"10.1200\/JCO.1990.8.6.963"},{"key":"E00014","doi-asserted-by":"crossref","unstructured":"Lieschke, G.J., Grail, D., Hodgson, G., Metcalf, D., Stanley, E., Cheers, C., et al. (1994). Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. <i>Blood, 84<\/i>, 1737-1746.","DOI":"10.1182\/blood.V84.6.1737.1737"},{"key":"E00015","doi-asserted-by":"crossref","unstructured":"Liu, F., Wu, H.Y., Wesselschmidt, R., Kornaga, T., & Link, D.C. (1996). Impaired production and increased apoptosis of neutrophils in granulocyte colony-stimulating factor receptor-deficient mice. <i>Immunity, 5<\/i>, 491-501.","DOI":"10.1016\/S1074-7613(00)80504-X"},{"key":"E00016","doi-asserted-by":"crossref","unstructured":"Lyman, G.H., Kuderer, N., Greene, J., & Balducci, L. (1998). The economics of febrile neutropenia: Implications for the use of colony-stimulating factors. <i>European Journal of Cancer, 34<\/i>, 1857-1864.","DOI":"10.1016\/S0959-8049(98)00222-6"},{"key":"E00017","unstructured":"Lyman, G.H., Morrison, V.A., Dale, D.C., Crawford, J., Delgado, D.J., & Fridman, M. (2002). Risk of first febrile neutropenia (FN) among patients receiving CHOP chemotherapy [Abstract 1430]. <i>Proceedings of the American Society of Clinical Oncology, 21<\/i>, 358a."},{"key":"E00018","doi-asserted-by":"crossref","unstructured":"Molineux, G., Kinstler, O., Briddell, B., Hartley, C., McElroy, P., Kerzic, P., et al. (1999). A new form of filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. <i>Experimental Hematology, 27<\/i>, 1724-1734.","DOI":"10.1016\/S0301-472X(99)00112-5"},{"key":"E00019","unstructured":"Moore, T., Shiftan, T.A., Knight, C.A., Vongkovit, P., Kalman, L.A., Axelson, J.A., et al. (2001). A prospective trial assessing a risk model for filgrastim use on chemotherapy (CT) dose intensity (DI) in the adjuvant treatment of stage I-III breast cancer patients (BCP) [Abstract 1778]. <i>Proceedings of the American Society of Clinical Oncology, 20<\/i>, 86."},{"key":"E00020","doi-asserted-by":"crossref","unstructured":"Ozer, H., Armitage, J.O., Bennett, C.L., Crawford, J., Demetri, G.D., Pizzo, P.A., et al. (2000). 2000 update of recommendations for the use of hemato-poietic colony-stimulating factors: Evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. <i>Journal of Clinical Oncology, 18<\/i>, 3558-3585.","DOI":"10.1200\/JCO.2000.18.20.3558"},{"key":"E00021","unstructured":"Rivera, E., Erder, H.M., Fridman, M., Brannan, C., Frye, D.K., & Hortobagyi, G.N. (2001). Delivering full planned dose on time (PDOT) chemotherapy (CT) while lowering the incidence of febrile neutropenia (FN) hospitalizations: Initial results from a prospective study providing filgrastim support to high risk breast cancer patients (BCP) [Abstract 3]. <i>Breast Cancer Research and Treatment, 69<\/i>, 209."},{"key":"E00022","doi-asserted-by":"crossref","unstructured":"Silber, J.H., Fridman, M., Shpilsky, A., Even-Shoshan, O., Smink, D.S., Jayaraman, J., et al. (1998). Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer. <i>Journal of Clinical Oncology, 16<\/i>, 2435-2444.","DOI":"10.1200\/JCO.1998.16.7.2435"},{"key":"E00023","doi-asserted-by":"crossref","unstructured":"Tamura, M., Hattori, K., Nomura, H., Oheda, M., Kobuta, N., Imazeki, I., et al. (1987). Induction of neutrophilic granulocytosis in mice by administration of purified human native granulocyte colony-stimulating factor (GCSF). <i>Biochemical and Biophysical Research Communications, 142<\/i>, 454-460.","DOI":"10.1016\/0006-291X(87)90296-8"},{"key":"E00024","doi-asserted-by":"crossref","unstructured":"Bennett, C.L., Hynes, D., Godwin, J., Stinson, T.J., Golub, R.M., & Appel-baum, F.R. (2001). Economic analysis of granulocyte colony stimulating factor as adjunct therapy for older patients with acute myelogenous leukemia (AML): Estimates from a Southwest Oncology Group clinical trial. <i>Cancer Investigation, 19<\/i>, 603-610.","DOI":"10.1081\/CNV-100104288"},{"key":"E00025","doi-asserted-by":"crossref","unstructured":"Beveridge, R.A., Miller, J.A., Kales, A.N., Binder, R.A., Robert, N.J., Harvey, J.H., et al. (1998). A comparison of the efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression. <i>Cancer Investigation, 16<\/i>, 366-373.","DOI":"10.3109\/07357909809115775"},{"key":"E00026","doi-asserted-by":"crossref","unstructured":"Blay, J.Y., Chauvin, F., Le Cesne, A., Anglaret, B., Bouhour, D., Lasset, C., et al. (1996). Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. <i>Journal of Clinical Oncology, 14<\/i>, 636-643.","DOI":"10.1200\/JCO.1996.14.2.636"},{"key":"E00027","doi-asserted-by":"crossref","unstructured":"Bodey, G.P., Buckley, M., Sathe, Y.S., & Freireich, E.J. (1966). Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. <i>Annals of Internal Medicine, 64<\/i>, 328-340.","DOI":"10.7326\/0003-4819-64-2-328"},{"key":"E00028","doi-asserted-by":"crossref","unstructured":"Bonadonna, G., & Valagussa, B.S. (1981). Dose-response effect of adjuvant chemotherapy in breast cancer. <i>New England Journal of Medicine, 304<\/i>, 10-15.","DOI":"10.1056\/NEJM198101013040103"},{"key":"E00029","doi-asserted-by":"crossref","unstructured":"Bonadonna, G., Valagussa, P., Moliterni, A., Zambetti, M., & Brambilla, C. (1995). Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: The results of 20 years of follow-up. <i>New England Journal of Medicine, 332<\/i>, 901-906.","DOI":"10.1056\/NEJM199504063321401"},{"key":"E00030","doi-asserted-by":"crossref","unstructured":"Bronchud, M.H., Potter, M.R., Morgenstern, G., Blasco, M.J., Scharffe, J.H., Thatcher, N., et al. (1988). In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients. <i>British Journal of Cancer, 58<\/i>, 64-69.","DOI":"10.1038\/bjc.1988.163"},{"key":"E00031","doi-asserted-by":"crossref","unstructured":"Budman, D.R., Berry, D.A., Cirrincione, C.T., Henderson, I.C., Wood, W.C., Weiss, R.B., et al. (1998). Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. <i>Journal of the National Cancer Institute, 90<\/i>, 1205-1211.","DOI":"10.1093\/jnci\/90.16.1205"},{"key":"E00032","doi-asserted-by":"crossref","unstructured":"Burg, N.D., & Pillinger, M.H. (2001). The neutrophil: Function and regulation in innate and humoral immunity. <i>Clinical Immunology, 99<\/i>, 7-17.","DOI":"10.1006\/clim.2001.5007"},{"key":"E00033","unstructured":"Caggiano, V., Stolshek, B., Delgado, D., & Carter, W. (2001). First and all-cycle febrile neutropenia hospitalization (FNH) and costs in intermediate grade non-Hodgkin's lymphoma (IGL) patients on standard-dose CHOP therapy [Abstract]. <i>Blood, 98<\/i>(Suppl. 1), 431a."},{"key":"E00034","doi-asserted-by":"crossref","unstructured":"Cebon, J., Layton, J.E., Maher, D., & Morstyn, G. (1994). Endogenous haemopoietic growth factors in neutropenia and infection. <i>British Journal of Haematology, 86<\/i>, 265-274.","DOI":"10.1111\/j.1365-2141.1994.tb04725.x"},{"key":"E00035","doi-asserted-by":"crossref","unstructured":"Chatta, G.S., Price, T.H., Stratton, J.R., & Dale, D.C. (1994). Aging and marrow neutrophil reserves. <i>Journal of the American Geriatrics Society, 42<\/i>(1), 77-81.","DOI":"10.1111\/j.1532-5415.1994.tb06077.x"},{"key":"E00036","doi-asserted-by":"crossref","unstructured":"Crawford, J., Kreisman, H., Garewal, H., Jones, S.E., Shoemaker, D., Pupa, M.R., et al. (1997). The impact of filgrastim schedule variation on hemato-poietic recovery post-chemotherapy. <i>Annals of Oncology, 8<\/i>, 1117-1124.","DOI":"10.1023\/A:1008271804151"},{"key":"E00037","doi-asserted-by":"crossref","unstructured":"Crawford, J., Ozer, H., Stoller, R., Johnson, D., Lyman, G., Tabarra, l., et al. (1991). Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. <i>New England Journal of Medicine, 325<\/i>, 164-170.","DOI":"10.1056\/NEJM199107183250305"},{"key":"E00038","unstructured":"Dexter, T.M., & Testa, N.G. (1993). <i>Haematopoietic growth factors: Review of biology and clinical potential.<\/i> Cheshire, England: Gardiner-Caldwell."},{"key":"E00039","doi-asserted-by":"crossref","unstructured":"Trillet-Lenoir, V., Green, J., Manegold, C., Von Pawel, J., Gatzemeier, U., Lebeau, B., et al. (1993). Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. <i>European Journal of Cancer, 29A<\/i>, 319-324.","DOI":"10.1016\/0959-8049(93)90376-Q"},{"key":"E00040","doi-asserted-by":"crossref","unstructured":"Welte, K., Gabrilove, J., Bronchud, M.H., Platzer, E., & Morstyn, G. (1996). Filgrastim (r-metHuG-CSF): The first 10 years. <i>Blood, 88<\/i>, 1907-1929.","DOI":"10.1182\/blood.V88.6.1907.bloodjournal8861907"}],"container-title":["Oncology Nursing Forum"],"original-title":[],"link":[{"URL":"http:\/\/ons.metapress.com\/index\/T81286T226061233.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:52:44Z","timestamp":1763754764000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/onf\/31\/3\/optimal-use-granulocyte-colony-stimulating-factor-patients-cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5,1]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,5,1]]}},"alternative-id":["T81286T226061233"],"URL":"https:\/\/doi.org\/10.1188\/04.onf.569-576","relation":{},"ISSN":["0190-535X","1538-0688"],"issn-type":[{"type":"print","value":"0190-535X"},{"type":"electronic","value":"1538-0688"}],"subject":[],"published":{"date-parts":[[2004,5,1]]}}}